Dr. Sanjay Kumar, MD
Cardiac Electrophysiology (Clinical Cardiac Electrophysiology Physician)
- Medicare participating
At a glance
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 804
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Clinical Cardiac Electrophysiology Physician primary
WI license 62805 -
Cardiovascular Disease Physician
WI license 62805 -
Hospitalist Physician
WI license 62805
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Marshfield Medical Center Marshfield, WI
- Spring Valley Hospital Medical Center Las Vegas, NV
- Monmouth Medical Center-Southern Campus Lakewood, NJ
- Marshfield Medical Center - Weston Weston, WI
- Marshfield Medical Center - Minocqua Minocqua, WI
Medical groups
- Mchs Hospitals Inc (1,197 clinicians)
- Apex Cardiology Associates PLLC (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 804
- Services billed
- 1,868
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 389 | 321 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 340 | 133 |
| Established patient office or other outpatient visit, 40-54 minutes | 206 | 181 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 145 | 136 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 110 | 95 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 93 | 77 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 74 | 70 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 72 | 56 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 68 | 58 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 59 | 43 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 4 payments worth $185 in total to this clinician.
| Medtronic, Inc. | $79.66 |
|---|---|
| Cvrx, Inc. | $77.74 |
| Bridgebio Pharma, Inc. | $16.21 |
| Zoll Services LLC (a/k/a Zoll Lifecor Corp) | $11.88 |
| Food and Beverage | $185 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $9,438 in research payments for these studies, mostly to the institutions running them.
- ARTEMIS RAvulizumab to PRotect PaTients with Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE) A Phase 3, Randomized, Double-b…
Alexion Pharmaceuticals, Inc. - Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)
Cvrx, Inc. · Terminated · NCT04502316
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.